In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 9.76 above Renovorx Inc average.

Within Major Pharmaceutical Preparations industry 109 other companies have achieved higher Quick Ratio than Renovorx Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 695, from total ranking in the second quarter 2026 at 1244.

Explain Quick Ratio?
How much Cash & cash equivalents RNXT�s has?
What are RNXT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RNXT/financial-strength

https://api.csimarket.com/api/v1/companies/RNXT/fundamentals

https://api.csimarket.com/api/v1/companies/RNXT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

RNXT Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	10.99 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	103.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	9.76	Subscribe	Subscribe	Subscribe	Subscribe
RNXT's Total Ranking	# 695	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	10.99 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	9.82 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 110
Healthcare Sector	# 168
Overall Market	# 474

Quick Ratio Statistics
High	Average	Low
28.36	7.5	0.83
(Sep 30 2021)		(Dec 31 2020)

Financial Statements
Renovorx Inc 's Current Liabilities	$ 2 Millions	Visit RNXT's Balance sheet
Renovorx Inc 's Cash & cash equivalent	$ 20 Millions	Visit RNXT's Balance sheet
Source of RNXT's Sales		Visit RNXT's Sales by Geography

Cumulative Renovorx Inc 's Quick Ratio

RNXT's Quick Ratio for the trailling 12 Months

RNXT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	10.9 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	32.37 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	7.43	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 261	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	2.71 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	21.58 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to RNXT Financial Strength Comparisons >> Go to Compare RNXT Quick Ratio to its Competitors

On the trailing twelve months basis RNXT Cash & cash equivalent more than doubled by 103.15 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Renovorx Inc 's Quick Ratio to 7.43, above RNXT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 417 other companies have achieved higher Quick Ratio than Renovorx Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 2683.

Explain Quick Ratio?
How much Cash & cash equivalents RNXT�s has?
What are RNXT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 418
Healthcare Sector	# 852
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.93	6.12	2.81
(Jun 30 2022)		(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Alto Neuroscience Inc	17.90	$ 319.344 Millions	$ 17.836 Millions
Upstream Bio Inc	17.34	$ 207.365 Millions	$ 11.960 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions
Tenax Therapeutics Inc	13.61	$ 113.700 Millions	$ 8.355 Millions
Corvus Pharmaceuticals Inc	13.25	$ 204.252 Millions	$ 15.418 Millions
Stablecoin Development Corporation	13.01	$ 7.153 Millions	$ 0.550 Millions
Uniqure N v	12.78	$ 768.430 Millions	$ 60.142 Millions
Rhythm Pharmaceuticals Inc	12.62	$ 320.944 Millions	$ 25.438 Millions
Dyne Therapeutics Inc	12.53	$ 1,134.386 Millions	$ 90.545 Millions

Date modified: 2026-11-06T13:00:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.